Moreover, throughout AD progression there is a reduction of AChE levels and an increase of those of a nonspecific cholinesterase, butyrylcholinesterase (BChE); thus, targeting the latter could result in higher therapeutic efficacy [20]. This evidence concerns the gene BCHE and Alzheimer disease.